Southwest Oncology Group is now 'SWOG'

NewsGuard 100/100 Score

The Southwest Oncology Group is now simply "SWOG."

The National Cancer Institute (NCI)-supported clinical trial cooperative group has used the acronym "SWOG" informally for decades. Now it's formal.

"The group was founded in Texas in 1956 and for many years had a membership heavily concentrated in the southwest U.S.," says SWOG Chair Laurence Baker, D.O. "But for several decades now we've been a national organization and in recent years even international, so continuing to refer to ourselves as the 'southwest' oncology group was misleading."

"It's what most of the research world and many of the patients who participate in our trials already know us as," he points out.

Leading cancer research. Together.
A survey of the group's membership of almost 9,000 research professionals resulted in a new tag line to go along with the name change. The tag line succinctly conveys what SWOG does and how it does it: Leading cancer research. Together.

"'Together' is key," says Baker. "The cooperative groups invented team science, and this team approach, with investigators and member sites spread all over the U.S. and beyond, is the secret to our success."

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Machine learning models identify immunophenotypes in NSCLC for immunotherapy guidance